WO2000021572A3 - Hydrogels and water soluble polymeric carriers for drug delivery - Google Patents
Hydrogels and water soluble polymeric carriers for drug delivery Download PDFInfo
- Publication number
- WO2000021572A3 WO2000021572A3 PCT/US1999/023396 US9923396W WO0021572A3 WO 2000021572 A3 WO2000021572 A3 WO 2000021572A3 US 9923396 W US9923396 W US 9923396W WO 0021572 A3 WO0021572 A3 WO 0021572A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug delivery
- hydrogels
- water soluble
- soluble polymeric
- polymeric carriers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/595—Polyamides, e.g. nylon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000575544A JP2002527408A (en) | 1998-10-09 | 1999-10-08 | Hydrogel and water-soluble polymer carrier for drug delivery |
CA002346329A CA2346329A1 (en) | 1998-10-09 | 1999-10-08 | Hydrogels and water soluble polymeric carriers for drug delivery |
EP99951843A EP1117444A2 (en) | 1998-10-09 | 1999-10-08 | Hydrogels and water soluble polymeric carriers for drug delivery |
AU64198/99A AU6419899A (en) | 1998-10-09 | 1999-10-08 | Hydrogels and water soluble polymeric carriers for drug delivery |
US10/445,026 US7186413B2 (en) | 1998-10-09 | 2003-05-27 | Hydrogels and water soluble polymeric carriers for drug delivery |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10359598P | 1998-10-09 | 1998-10-09 | |
US60/103,595 | 1998-10-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09830955 A-371-Of-International | 1999-10-08 | ||
US10/445,026 Division US7186413B2 (en) | 1998-10-09 | 2003-05-27 | Hydrogels and water soluble polymeric carriers for drug delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000021572A2 WO2000021572A2 (en) | 2000-04-20 |
WO2000021572A3 true WO2000021572A3 (en) | 2000-11-30 |
Family
ID=22296010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/023396 WO2000021572A2 (en) | 1998-10-09 | 1999-10-08 | Hydrogels and water soluble polymeric carriers for drug delivery |
Country Status (6)
Country | Link |
---|---|
US (1) | US7186413B2 (en) |
EP (2) | EP1117444A2 (en) |
JP (1) | JP2002527408A (en) |
AU (1) | AU6419899A (en) |
CA (1) | CA2346329A1 (en) |
WO (1) | WO2000021572A2 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8906381B2 (en) | 2008-10-12 | 2014-12-09 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IGG humoral response without T-cell antigen |
US8932595B2 (en) | 2008-10-12 | 2015-01-13 | Massachusetts Institute Of Technology | Nicotine immunonanotherapeutics |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
US9233072B2 (en) | 2008-10-12 | 2016-01-12 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
US9308280B2 (en) | 2008-10-12 | 2016-04-12 | Massachusetts Institute Of Technology | Targeting of antigen presenting cells with immunonanotherapeutics |
US9333179B2 (en) | 2007-04-04 | 2016-05-10 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US9474717B2 (en) | 2007-10-12 | 2016-10-25 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
CN107049930A (en) * | 2017-03-30 | 2017-08-18 | 广东泰宝医疗科技股份有限公司 | A kind of promoting healing wound gel and preparation method thereof |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070053939A1 (en) * | 2003-10-17 | 2007-03-08 | Hideakira Yokoyama | Biguanide drug-containing jelly preparation |
EP1732973A1 (en) | 2004-02-23 | 2006-12-20 | E.I.Du pont de nemours and company | Crosslinked polymers containing biomass derived materials |
US9561309B2 (en) * | 2004-05-27 | 2017-02-07 | Advanced Cardiovascular Systems, Inc. | Antifouling heparin coatings |
EP2594291A1 (en) * | 2004-07-05 | 2013-05-22 | Ascendis Pharma GmbH | Hydrogel |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
WO2006016248A1 (en) * | 2004-08-05 | 2006-02-16 | Firmenich Sa | Use of dynamic mixtures for a controlled release of fragrances |
EP1960009B1 (en) | 2005-12-13 | 2011-11-23 | The President and Fellows of Harvard College | Scaffolds for cell transplantation |
US9603941B2 (en) * | 2006-01-24 | 2017-03-28 | Minghui Chai | Method of preparing dendritic drugs |
WO2007133807A2 (en) * | 2006-05-15 | 2007-11-22 | Massachusetts Institute Of Technology | Polymers for functional particles |
CN101557801B (en) * | 2006-07-14 | 2013-10-30 | Fmc生物聚合物联合股份有限公司 | Hydrogels containing low molecular weight alginates and biostructures made therefrom |
EP1985286A1 (en) * | 2007-04-24 | 2008-10-29 | Biocompatibles UK Limited | Microspheres for treatment of brain tumours |
WO2008137831A1 (en) * | 2007-05-07 | 2008-11-13 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Water-soluble nanoparticles containing water-insoluble compounds |
WO2009002401A2 (en) | 2007-06-21 | 2008-12-31 | President And Fellows Of Harvard College | Scaffolds for cell collection or elimination |
US9370558B2 (en) | 2008-02-13 | 2016-06-21 | President And Fellows Of Harvard College | Controlled delivery of TLR agonists in structural polymeric devices |
US10328133B2 (en) | 2008-02-13 | 2019-06-25 | President And Fellows Of Harvard College | Continuous cell programming devices |
CA2722425A1 (en) * | 2008-04-28 | 2009-11-05 | Surmodics, Inc. | Poly-.alpha.(1-4)glucopyranose-based matrices with hydrazide crosslinking |
WO2009146456A1 (en) | 2008-05-30 | 2009-12-03 | President And Fellows Of Harvard College | Controlled release of growth factors and signaling molecules for promoting angiogenesis |
WO2010074958A1 (en) * | 2008-12-22 | 2010-07-01 | The Trustees Of The University Of Pennsylvania | Hydrolytically degradable polysaccharide hydrogels |
WO2010093528A2 (en) * | 2009-02-10 | 2010-08-19 | President And Fellows Of Harvard College | On-demand and reversible drug release by external cue |
WO2010120749A2 (en) | 2009-04-13 | 2010-10-21 | President And Fellow Of Harvard College | Harnessing cell dynamics to engineer materials |
ES2636741T3 (en) | 2009-07-31 | 2017-10-09 | Sanofi-Aventis Deutschland Gmbh | Long-acting insulin composition |
AU2010278702C1 (en) | 2009-07-31 | 2016-07-14 | Forsyth Dental Infirmary For Children | Programming of cells for tolerogenic therapies |
WO2011012718A1 (en) | 2009-07-31 | 2011-02-03 | Ascendis Pharma As | Prodrugs comprising an insulin linker conjugate |
US8492339B2 (en) * | 2009-10-26 | 2013-07-23 | Empire Technology Development Llc | Angiogenesis promoted by caged growth factors |
PT104879B (en) * | 2009-12-10 | 2012-10-17 | Univ Do Minho | DEXTRINO HYDROGEL FOR BIOMEDICAL APPLICATIONS |
WO2011075516A2 (en) * | 2009-12-18 | 2011-06-23 | President And Fellows Of Harvard College | Active scaffolds for on-demand drug and cell delivery |
WO2011100460A2 (en) * | 2010-02-11 | 2011-08-18 | Ecole Polytechnique Federale De Lausanne | Ccr7 ligand delivery and co-delivery in immunotherapy |
EP2542230A4 (en) * | 2010-03-05 | 2013-08-28 | Harvard College | Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1 |
EP2585053A4 (en) | 2010-06-25 | 2014-02-26 | Harvard College | Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones |
EP2438930A1 (en) | 2010-09-17 | 2012-04-11 | Sanofi-Aventis Deutschland GmbH | Prodrugs comprising an exendin linker conjugate |
KR102155383B1 (en) | 2010-10-06 | 2020-09-11 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Injectable, pore-forming hydrogels for materials-based cell therapies |
US9603894B2 (en) | 2010-11-08 | 2017-03-28 | President And Fellows Of Harvard College | Materials presenting notch signaling molecules to control cell behavior |
US10285943B2 (en) | 2010-12-02 | 2019-05-14 | Greenmark Biomedical Inc. | Aptamer bioconjugate drug delivery device |
US9486404B2 (en) | 2011-03-28 | 2016-11-08 | The Trustees Of The University Of Pennsylvania | Infarction treatment compositions and methods |
GB201105226D0 (en) | 2011-03-29 | 2011-05-11 | Univ Leiden | Methods |
WO2012148684A1 (en) | 2011-04-27 | 2012-11-01 | President And Fellows Of Harvard College | Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation |
WO2012149358A1 (en) | 2011-04-28 | 2012-11-01 | President And Fellows Of Harvard College | Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration |
US9675561B2 (en) | 2011-04-28 | 2017-06-13 | President And Fellows Of Harvard College | Injectable cryogel vaccine devices and methods of use thereof |
AU2012261848B2 (en) | 2011-06-03 | 2017-06-15 | President And Fellows Of Harvard College | In situ antigen-generating cancer vaccine |
WO2012176023A1 (en) | 2011-06-23 | 2012-12-27 | Indian Institute Of Technology Kanpur | Hydrogel scaffolds for tissue engineering |
US8753309B2 (en) | 2011-06-24 | 2014-06-17 | The Invention Science Fund I, Llc | Device, system, and method including micro-patterned cell treatment array |
US9321787B2 (en) * | 2011-07-07 | 2016-04-26 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-d]pyrimidine ring |
WO2013082149A1 (en) | 2011-11-28 | 2013-06-06 | Case Western Reserve University | Polysaccharide therapeutic conjugates |
PT2838515T (en) | 2012-04-16 | 2020-02-25 | Harvard College | Mesoporous silica compositions for modulating immune responses |
CA2790763A1 (en) * | 2012-05-31 | 2013-11-30 | Ecosynthetix Ltd. | Aptamer bioconjugate drug delivery device |
US10918765B2 (en) | 2013-04-11 | 2021-02-16 | University Of Vermont And State Agricultural College | Decellularization and recellularization of whole organs |
US20170119892A1 (en) * | 2014-04-04 | 2017-05-04 | President And Fellows Of Harvard College | Refillable drug delivery devices and methods of use thereof |
JP7348708B2 (en) | 2014-04-30 | 2023-09-21 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Combination vaccine device and method for killing cancer cells |
US10471118B2 (en) | 2014-05-30 | 2019-11-12 | Case Western Reserve University | Retinylamine derivitives for treatment of ocular disorders |
US11129845B2 (en) | 2014-06-18 | 2021-09-28 | Case Western Reserve University | Compositions and methods for the delivery of nucleic acids |
US10925980B2 (en) | 2014-08-04 | 2021-02-23 | Case Western Reserve University | Molecular probes and methods of use |
EP3250250A4 (en) * | 2015-01-30 | 2019-05-22 | President and Fellows of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
US10849927B2 (en) * | 2015-03-20 | 2020-12-01 | Howard University | Polysaccharide-polyamine copolymers for removal of phosphate |
US11150242B2 (en) | 2015-04-10 | 2021-10-19 | President And Fellows Of Harvard College | Immune cell trapping devices and methods for making and using the same |
US11407786B2 (en) | 2015-06-18 | 2022-08-09 | Case Western Reserve University | Compositions and methods for the delivery of nucleic acids |
EP3821880A1 (en) * | 2015-10-26 | 2021-05-19 | President and Fellows of Harvard College | Oxidized polysaccharides and methods of use thereof |
US11752238B2 (en) | 2016-02-06 | 2023-09-12 | President And Fellows Of Harvard College | Recapitulating the hematopoietic niche to reconstitute immunity |
US9901649B2 (en) | 2016-05-03 | 2018-02-27 | International Business Machines Corporation | Block copolymers for therapeutic drug delivery |
JP2019522486A (en) | 2016-07-13 | 2019-08-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | Antigen presenting cell mimetic scaffold and methods for making and using the same |
JOP20190245A1 (en) | 2017-04-20 | 2019-10-15 | Novartis Ag | Sustained release delivery systems comprising traceless linkers |
JP2021519310A (en) | 2018-03-28 | 2021-08-10 | グリーンマーク バイオメディカル インコーポレイテッドGreenMark Biomedical, Inc. | Phosphate cross-linked starch nanoparticles and dental treatment |
TW202027794A (en) | 2018-10-03 | 2020-08-01 | 瑞士商諾華公司 | Sustained delivery of angiopoetin-like 3 polypeptides |
WO2020094776A1 (en) | 2018-11-07 | 2020-05-14 | Universiteit Maastricht | Bioinks |
JP2022549886A (en) * | 2019-09-27 | 2022-11-29 | シギロン セラピューティクス, インコーポレイテッド | Methods for Evaluating Small Molecule Modified Polymers in Compositions |
CN113546041B (en) * | 2021-06-18 | 2022-04-29 | 中国海洋大学 | Polyguluronic acid sulfate-adriamycin polymer micelle and preparation method and application thereof |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1178837B (en) * | 1957-08-01 | 1964-10-01 | Therapeutique Lab Franc De | Process for the preparation of hydrazone derivatives of starch |
US4489065A (en) * | 1981-07-02 | 1984-12-18 | Valcor Scientific Ltd. | Chondroitin drug Complexes |
EP0251905A2 (en) * | 1986-06-30 | 1988-01-07 | FIDIA S.p.A. | Esters of alginic acid |
WO1994007536A2 (en) * | 1992-09-25 | 1994-04-14 | Keele University | Alginate-bioactive agent conjugates |
EP0652015A2 (en) * | 1993-10-15 | 1995-05-10 | Bristol-Myers Squibb Company | A sustained release composition comprising a multivalent cation cross-linked algenate combined with a polyacrylic acid |
WO1995030411A1 (en) * | 1994-05-09 | 1995-11-16 | Korea Research Institute Of Chemical Technology | Transdermal drug delivery system having ionic polymer networks |
WO1996024377A1 (en) * | 1995-02-10 | 1996-08-15 | Christian Noe | Medicament in particle form |
WO1998012228A1 (en) * | 1996-09-19 | 1998-03-26 | The Regents Of The University Of Michigan | Polymers containing polysaccharides such as alginates or modified alginates |
EP0947201A1 (en) * | 1998-02-04 | 1999-10-06 | Roche Diagnostics GmbH (HRB 3962 - vormals Boehringer Mannheim GmbH) | Pharmaceutical composition of hedgehog proteins and use thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5192661A (en) * | 1987-08-04 | 1993-03-09 | University Of Ottawa | Multicomponent kit containing an antibody to a synthetic antigen of sialic acid |
JP2796852B2 (en) * | 1988-10-31 | 1998-09-10 | インターナショナル・ビジネス・マシーンズ・コーポレーション | Magnetic storage device and method |
US5474765A (en) * | 1992-03-23 | 1995-12-12 | Ut Sw Medical Ctr At Dallas | Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells |
AU4406793A (en) * | 1992-06-04 | 1993-12-30 | Clover Consolidated, Limited | Water-soluble polymeric carriers for drug delivery |
NZ250375A (en) * | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
US5547981A (en) * | 1993-03-09 | 1996-08-20 | Enzon, Inc. | Taxol-7-carbazates |
AU7097094A (en) * | 1993-06-01 | 1994-12-20 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
US5616568A (en) * | 1993-11-30 | 1997-04-01 | The Research Foundation Of State University Of New York | Functionalized derivatives of hyaluronic acid |
-
1999
- 1999-10-08 CA CA002346329A patent/CA2346329A1/en not_active Abandoned
- 1999-10-08 EP EP99951843A patent/EP1117444A2/en not_active Withdrawn
- 1999-10-08 AU AU64198/99A patent/AU6419899A/en not_active Abandoned
- 1999-10-08 WO PCT/US1999/023396 patent/WO2000021572A2/en not_active Application Discontinuation
- 1999-10-08 JP JP2000575544A patent/JP2002527408A/en not_active Withdrawn
- 1999-10-08 EP EP03012442A patent/EP1374908A3/en not_active Withdrawn
-
2003
- 2003-05-27 US US10/445,026 patent/US7186413B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1178837B (en) * | 1957-08-01 | 1964-10-01 | Therapeutique Lab Franc De | Process for the preparation of hydrazone derivatives of starch |
US4489065A (en) * | 1981-07-02 | 1984-12-18 | Valcor Scientific Ltd. | Chondroitin drug Complexes |
EP0251905A2 (en) * | 1986-06-30 | 1988-01-07 | FIDIA S.p.A. | Esters of alginic acid |
WO1994007536A2 (en) * | 1992-09-25 | 1994-04-14 | Keele University | Alginate-bioactive agent conjugates |
EP0652015A2 (en) * | 1993-10-15 | 1995-05-10 | Bristol-Myers Squibb Company | A sustained release composition comprising a multivalent cation cross-linked algenate combined with a polyacrylic acid |
WO1995030411A1 (en) * | 1994-05-09 | 1995-11-16 | Korea Research Institute Of Chemical Technology | Transdermal drug delivery system having ionic polymer networks |
WO1996024377A1 (en) * | 1995-02-10 | 1996-08-15 | Christian Noe | Medicament in particle form |
WO1998012228A1 (en) * | 1996-09-19 | 1998-03-26 | The Regents Of The University Of Michigan | Polymers containing polysaccharides such as alginates or modified alginates |
EP0947201A1 (en) * | 1998-02-04 | 1999-10-06 | Roche Diagnostics GmbH (HRB 3962 - vormals Boehringer Mannheim GmbH) | Pharmaceutical composition of hedgehog proteins and use thereof |
Non-Patent Citations (4)
Title |
---|
BOUHADIR, K. H. (1) ET AL: "Synthesis and cross-linking of partially oxidized alginate for tissue engineering applications.", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, (1998) VOL. 216, NO. 1-3, PP. BTEC 78. MEETING INFO.: 216TH NATIONAL MEETING OF THE AMERICAN CHEMICAL SOCIETY BOSTON, MASSACHUSETTS, USA AUGUST 23-27, 1998 AMERICAN CHEMICAL SOCIETY., August 1998 (1998-08-01), XP000901592 * |
BOUHADIR, KAMAL H. ET AL: "Biodegradable hydrogels for controlled cell and drug delivery", POLYM. PREPR. (AM. CHEM. SOC., DIV. POLYM. CHEM.) (1999), 40(1), 501-502, 1999, XP000901532 * |
HEINDEL N D ET AL: "HYDRAZIDE PHARMACEUTICALS AS CONJUGATES TO POLYALDEHYDE DEXTRAN: SYNTHESES, CHARACTERIZATION, AND STABILITY", BIOCONJUGATE CHEMISTRY,US,AMERICAN CHEMICAL SOCIETY, WASHINGTON, vol. 1, no. 1, 1 January 1990 (1990-01-01), pages 77 - 82, XP000236575, ISSN: 1043-1802 * |
LEE, KUEN YONG ET AL: "Degradation Behavior of Covalently Crosslinked Poly(aldehyde guluronate) Hydrogels", MACROMOLECULES (2000), 33(1), 97-101, 2000, XP000901406 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
US9381477B2 (en) | 2006-06-23 | 2016-07-05 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
US9217129B2 (en) | 2007-02-09 | 2015-12-22 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
US9333179B2 (en) | 2007-04-04 | 2016-05-10 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
US9474717B2 (en) | 2007-10-12 | 2016-10-25 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9526702B2 (en) | 2007-10-12 | 2016-12-27 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9539210B2 (en) | 2007-10-12 | 2017-01-10 | Massachusetts Institute Of Technology | Vaccine nanotechnology |
US9308280B2 (en) | 2008-10-12 | 2016-04-12 | Massachusetts Institute Of Technology | Targeting of antigen presenting cells with immunonanotherapeutics |
US9233072B2 (en) | 2008-10-12 | 2016-01-12 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US9439859B2 (en) | 2008-10-12 | 2016-09-13 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunoanotherapeutics |
US8906381B2 (en) | 2008-10-12 | 2014-12-09 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IGG humoral response without T-cell antigen |
US8932595B2 (en) | 2008-10-12 | 2015-01-13 | Massachusetts Institute Of Technology | Nicotine immunonanotherapeutics |
CN107049930A (en) * | 2017-03-30 | 2017-08-18 | 广东泰宝医疗科技股份有限公司 | A kind of promoting healing wound gel and preparation method thereof |
CN107049930B (en) * | 2017-03-30 | 2020-06-23 | 广东泰宝医疗科技股份有限公司 | Wound healing promoting gel and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
AU6419899A (en) | 2000-05-01 |
EP1374908A3 (en) | 2004-03-24 |
US20040028745A1 (en) | 2004-02-12 |
EP1374908A2 (en) | 2004-01-02 |
JP2002527408A (en) | 2002-08-27 |
CA2346329A1 (en) | 2000-04-20 |
WO2000021572A2 (en) | 2000-04-20 |
US7186413B2 (en) | 2007-03-06 |
EP1117444A2 (en) | 2001-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000021572A3 (en) | Hydrogels and water soluble polymeric carriers for drug delivery | |
AU2740997A (en) | Slow-release, self-absorbing, drug delivery system | |
EP1080231A4 (en) | Multimolecular devices, drug delivery systems and single-molecule selection | |
AU3177700A (en) | Polymers, their preparation and uses | |
WO1999036099A8 (en) | Sustained release compositions, process for producing the same and utilization thereof | |
AU5914999A (en) | Controlled release drug delivery | |
EP1026189A4 (en) | Thermoplastic dicyclopentadiene-base open-ring polymers, hydrogenated derivatives thereof, and processes for the preparation of both | |
WO2003011226A3 (en) | Products and drug delivery vehicles | |
AU4769900A (en) | Nicotine delivery systems | |
CA2346011A1 (en) | Hybrid nanofibril matrices for use as tissue engineering devices | |
DE69721481D1 (en) | DELAYED RELEASE ACTIVE SUBSTANCE FORMULATIONS | |
AU3764899A (en) | High molecular weight polyols, process for preparation and use thereof | |
AU2003214133A1 (en) | Topical composition comprising a cyclofructan, a carrier and a drug | |
ZA200203443B (en) | Medical bandaging product with tubular-knitted substrate. | |
AU697005B2 (en) | Implantable molded articles for the administration of active substances to plants | |
ZA200110536B (en) | 1,2,3,4,5,6-hexahydroazepino [4,5-b]indoles containing arylsulfones at the 9-position. | |
ZA97976B (en) | Uniform drug delivery theraphy. | |
AU3307600A (en) | Pyridine.imine polymerisation catalysts | |
MXPA01008148A (en) | Epothilon derivatives, method for the production and the use thereof as pharmaceuticals. | |
AU4905700A (en) | Neural transplantation delivery system | |
ZA200000610B (en) | Micro-osmotic controlled drug delivery systems. | |
WO1999036100A3 (en) | Polymeric carrier | |
AU7569796A (en) | Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds. | |
WO1999042593A8 (en) | Compositions and methods for sensitizing and inhibiting growth of human tumor cells | |
AU1210201A (en) | Direct method for preparing doped polyaniline, product prepared thereby and resinous articles containing said product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref country code: AU Ref document number: 1999 64198 Kind code of ref document: A Format of ref document f/p: F |
|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
ENP | Entry into the national phase |
Ref document number: 2346329 Country of ref document: CA Ref country code: CA Ref document number: 2346329 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 575544 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999951843 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 64198/99 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999951843 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09830955 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999951843 Country of ref document: EP |